Patient Voice in Rare Disease Medical Product Development
Hybrid Public Meeting
October 16, 2026 | 1-5pm (eastern)
The Foundation, in collaboration with the FDA, convened a hybrid public meeting to explore the patient voice in rare disease medical product development (biologic, drug, and device). The meeting explored where the patient voice is sought across the development timeline, its impact, and additional opportunities for patients to engage in the product development process. Insights from these discussions will help inform recommendations for product developers and regulators to consider as they advance patient-centered approaches in their work.
Questions? Contact us at admin@reaganudall.org.
This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an award of $135,770 in federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit FDA.gov.